Tang J X, Na N, Li J J, Fan L, Weng R H, Jiang N
Department of Hepatic Surgery and Liver Transplantation Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Department of Kidney Transplantation, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Transplant Proc. 2018 Jan-Feb;50(1):33-41. doi: 10.1016/j.transproceed.2017.11.034.
Controlled donation after cardiac death (CDCD) is increasingly common for liver transplantation due to donor shortage. However, the outcomes, in terms of grafts and recipients, remain unclear. The current study is a systematic review and meta-analysis that compared CDCD with donation after brain death (DBD).
We conducted an electronic search of MEDLINE, EMBASE, and the Cochrane Database (from January 2007 to May 2017). Studies reporting Maastricht category III or IV CDCD liver transplantation were screened for inclusion. We appraised studies using the Newcastle-Ottawa scale and meta-analyzed using a fixed or random effects model.
A total of 21 studies, with 12,035 patients, were included in data analysis. CDCD did not differ from DBD in patient survival (hazard ration: 1.20; 95% confidence interval [CI]: 0.98 to 1.47; P = .07), graft survival (hazard ratio: 1.24; 95% CI: 0.99 to 1.56; P = .06), primary nonfunction (odds ratio [OR]: 1.74; 95% CI: 1.00 to 3.03; P = .05), hepatic artery thrombosis (OR: 1.17; 95% CI: 0.78 to 1.74; P = .45). However, CDCD was associated with biliary complications (OR: 2.48; 95% CI: 2.05 to 3.00), retransplantation (OR: 2.54; 95% CI: 1.99 to 3.26), and peak alanine aminotransferase (weighted mean difference: 330.88; 95% CI: 259.88 to 401.87). A subgroup analysis that included only hepatitis C virus (HCV)-positive recipients showed no significant difference between CDCD and DBD in biliary complications (P = .16), retransplantion (P = .15), HCV recurrence (P = .20), and peak alanine aminotransferase (P = .06).
CDCD transplantation is the most viable alternative to DBD transplantation in the current critical shortage of liver organs. HCV infection may not be the inferior factor of postoperative outcomes and survival.
由于供体短缺,心脏死亡后器官捐献(CDCD)在肝移植中越来越普遍。然而,就移植物和受者而言,其结果仍不明确。本研究是一项系统评价和荟萃分析,比较了CDCD与脑死亡后器官捐献(DBD)。
我们对MEDLINE、EMBASE和Cochrane数据库进行了电子检索(2007年1月至2017年5月)。筛选纳入报告马斯特里赫特III类或IV类CDCD肝移植的研究。我们使用纽卡斯尔-渥太华量表评估研究,并使用固定或随机效应模型进行荟萃分析。
共有21项研究、12035例患者纳入数据分析。CDCD与DBD在患者生存率(风险比:1.20;95%置信区间[CI]:0.98至1.47;P = 0.07)、移植物生存率(风险比:1.24;95% CI:0.99至1.56;P = 0.06)、原发性无功能(比值比[OR]:1.74;95% CI:1.00至3.03;P = 0.05)、肝动脉血栓形成(OR:1.17;95% CI:0.78至1.74;P = 0.45)方面无差异。然而,CDCD与胆道并发症(OR:2.48;95% CI:2.05至3.00)、再次移植(OR:2.54;95% CI:1.99至3.26)以及谷丙转氨酶峰值(加权平均差:330.88;95% CI:259.88至401.87)相关。一项仅纳入丙型肝炎病毒(HCV)阳性受者的亚组分析显示,CDCD与DBD在胆道并发症(P = 0.16)、再次移植(P = 0.15)、HCV复发(P = 0.20)和谷丙转氨酶峰值(P = 0.06)方面无显著差异。
在当前肝脏器官严重短缺的情况下,CDCD移植是DBD移植最可行的替代方案。HCV感染可能不是术后结局和生存的不利因素。